As George Bernard Shaw once said, "Nothing is ever done in this world until men are prepared to kill one another if it is not done." While accidental fatalities, even those caused by preventable mistakes and human errors, are a far cry from murder, Don Berwick, MD, has seen enough death. He's also heard enough rhetoric about ways to improve healthcare quality.
The American Heart Association (AHA) Scientific Sessions comprise the largest meeting of its kind held in the cardiovascular field, with several thousand presentations given each year. The recently concluded 2004 AHA Scientific Sessions, which took place in New Orleans, included presentations of trials that evaluated potential therapeutic compounds, as well as widely used and accepted compounds in new dosages or combinations, for the treatment of cardiovascular disorders. The compilation of clinical news that follows focuses on the cardiovascular pharmacotherapy trials of greatest interest to formulary decision-makers, including: CREATE, PEACE, A-HeFT, PROTECT, CLEAR Platelets, DIPOM, GEMINI, SHIELD, and RIO-NA.
Secretary Tommy G. Thompson resigns, EPA administrator Michael Leavitt nominated replacement; HHS purchases 1.2 million doses of flu vaccine
A review of select agents in late-stage development for the treatment of arrhythmia, congestive/chronic heart failure, and pulmonary hypertension (PDF) (January 2005)
Serious infections due to the Aspergillus and Candida species and other filamentous fungi have emerged as an increasing cause of infectious morbidity and mortality in the United States and globally. The most notable explanation for this increase is a rise in the number of immunocompromised patients due to advances in transplantation, the emergence and prevalence of Acquired Immunodeficiency Syndrome (AIDS), and an increase in the number of invasive surgical procedures. 1-3 Treatment of these infections with currently available standard antifungal agents such as amphotericin B, itraconazole, and fluconazole still results in an unacceptably high associated mortality. 3. Furthermore, many of these antifungal agents have limitations, including dose-limiting toxicity, drug-drug interactions, and fungal resistance. 4-10
Transparency among PBMs continues to be an important strategy that should be approached openly.
Small business has its own distinct list of needs for health benefits.
California clinicians gather to share information for the benefit of all.
Jan. DTR Analysis: Successful PBMs establish trust
In early 2004, prestigious Oschner Clinic Foundation sold its 125,000-member health plan to Humana. The sale was the latest, most visible example of an industry trend.
Services offered by PBMs
Migraine headaches can be so painful that patients want to stay in a dark, quiet room until the pain subsides. They have a throbbing or pulsating quality, and they're often only on one side of the head.
HSAs are popular, but will they really change the economics of healthcare for the better?
SHORTLY AFTER the Allied victory in 1945, Albert Einstein produced one of his most-famous quotes: "I do not know what will be used in the next world war?assuming there will be another one?but the fourth world war will be fought with stones."An ominous statement from a truly brilliant man, to be sure. Hopefully, we'll never have to find out, but even if the next war is fought with clubs and rocks, there will still be a need for medical specialists to take care of the wounded.
We are approaching the time of year when health insurers are beginning to calculate loss ratios and compile other financial data in order to evaluate the performance of their book of business. They will evaluate each market segment and product line, and make underwriting and rating decisions as to each.
What would you think if I told you that a country could provide healthcare coverage for its population of 6.8 million without collecting a single dollar in taxes from two-thirds of those people? Would you be intrigued?
Three studies comprising more than 3,000 primary-care patients sought to demonstrate that flexible or semi-flexible dosing of zolpidem 10 mg was effective and safe in a general practice context.
There is a growing interest in the study of insomnia; this is reflected in emerging trends in clinical management and increased research. One key question is being asked: Is insomnia a symptom or a disease?
Long-term insomnia is a substantial problem. Of the 50% of the population that report sleep difficulties, up to 36% report symptoms of insomnia lasting more than 1 year.
Approximately 11%-12% of elementary school children experience daytime sleepiness, and up to 21% have fatigue during the school day.
Sleep plays an important role in energy homoeostasis. A study was conducted to test the hypothesis that circulating levels of leptin are influenced by sleep duration.
Researchers conducted a study to determine if self-reported sleep deprivation is associated with an increased risk of coronary events.
In each issue, the Focus On article reviews a newly approved or investigational drug of interest to pharmacy and therapeutics committee members. Because so many readers have told the editors of Formulary that they reference this column frequently when making formulary decisions for their hospitals, health-systems, or managed-care organizations, the editors have compiled this review of all the Focus On articles published in 2004, along with updates on the status of each agent.
As initiatives to legalize the importation of prescription drugs draw more attention, the concern over counterfeit drugs is growing. The possibility of receiving counterfeit drugs has created an emerging dilemma for health-care professionals. FDA is relying on pharmacists to help ensure the integrity of drug products before they reach health-care consumers. Pharmacy and therapeutics committees can play a key role in achieving this goal by reviewing policies for medication acquisition and ensuring that necessary controls are in place to help prevent the acquisition of counterfeit drugs. FDA is also taking steps to help alleviate counterfeiting by mandating bar codes on all hospital drug packaging and implementing electronic pedigree papers to track distribution. FDA leaders project that by 2007, all prescription drugs will be tracked electronically to help ensure their authenticity. Formulary decision-makers, pharmacy directors, and clinicians must continue to be educated about the problem to help prevent counterfeit drugs from polluting the drug supply.
Government, industry provide pharmaceutical policy outlook for 2005; $139 million to advance information technology, records; Rofecoxib hearings point to failures in clinical testing design, decision-making transparency; New guidance for generic drugs clarifies protocol, increases speed to market
New molecular entities: erlotinib, solifenacin, natalizumab
Worldwide study finds that fluoroquinolones are still effective against CAP; Weekly nesiritide may have greatest benefit in highest-risk heart failure patients
Valdecoxib meta-analysis finds increased cardiovascular risk
Agencies encourage development of more affordable treatments and take steps to ensure safer product use
December DTR Analysis: National HMO Enrollment by State